-
Something wrong with this record ?
Clonal hierarchy of main molecular lesions in acute myeloid leukaemia
Z. Herudkova, M. Culen, A. Folta, I. Jeziskova, J. Cerna, T. Loja, N. Tom, J. Smejkal, L. Semerad, D. Dvorakova, J. Mayer, Z. Racil
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
MUNI/A/1105/2018
Masarykova Univerzita
Ministerstvo Zdravotnictví Ceské Republiky
PubMed
31822038
DOI
10.1111/bjh.16341
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute drug therapy genetics therapy MeSH
- Clone Cells MeSH
- Adult MeSH
- Genes, Neoplasm * MeSH
- Heterografts MeSH
- Clonal Evolution MeSH
- Combined Modality Therapy MeSH
- Leukocytes MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Mutation * MeSH
- Mice, Inbred NOD MeSH
- Mice MeSH
- Neoplastic Stem Cells MeSH
- Neoplasm Proteins genetics MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Recurrence MeSH
- Aged MeSH
- Hematopoietic Stem Cell Transplantation MeSH
- Neoplasm Transplantation MeSH
- Animals MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Mice MeSH
- Aged MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Genetic mutations in acute myeloid leukaemia (AML) are assumed to occur in a sequential order; however, the predominant hierarchical roles of specific mutated genes have not been fully described. In this study, we aimed to determine the clonal involvement of the most frequent AML-associated mutations. Using a targeted sequencing panel for 18 genes, we traced changes and relative clonal contribution of mutations in 52 patients. We analysed 35 pairs of diagnosis and relapse samples, 27 pairs of primary samples and corresponding patient-derived xenografts, and 34 pairs of total leukocytes and corresponding isolated primitive cells or blast populations. In both relapse and xenografts, we observed conservation of main leukaemic clones and variability was limited to subclones with late-acquired mutations. AML evolution thus mainly involved modification of subclones while the clonal background remained unchanged. NPM1 mutations were identified as the most probable leukaemia-transformation lesion, remaining conserved in contrast to high variation of accompanying subclonal FLT3 and NRAS mutations. DNMT3A mutations represented the most stable mutations forming a preleukaemic background in most samples. Mutations in genes IDH1/2, TET2, RUNX1, ASXL1 and U2AF1 were detected both as preleukaemic and as subclonal lesions, suggesting a non-specific order of acquisition.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012302
- 003
- CZ-PrNML
- 005
- 20210714132203.0
- 007
- ta
- 008
- 210420s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.16341 $2 doi
- 035 __
- $a (PubMed)31822038
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Herudkova, Zdenka $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 245 10
- $a Clonal hierarchy of main molecular lesions in acute myeloid leukaemia / $c Z. Herudkova, M. Culen, A. Folta, I. Jeziskova, J. Cerna, T. Loja, N. Tom, J. Smejkal, L. Semerad, D. Dvorakova, J. Mayer, Z. Racil
- 520 9_
- $a Genetic mutations in acute myeloid leukaemia (AML) are assumed to occur in a sequential order; however, the predominant hierarchical roles of specific mutated genes have not been fully described. In this study, we aimed to determine the clonal involvement of the most frequent AML-associated mutations. Using a targeted sequencing panel for 18 genes, we traced changes and relative clonal contribution of mutations in 52 patients. We analysed 35 pairs of diagnosis and relapse samples, 27 pairs of primary samples and corresponding patient-derived xenografts, and 34 pairs of total leukocytes and corresponding isolated primitive cells or blast populations. In both relapse and xenografts, we observed conservation of main leukaemic clones and variability was limited to subclones with late-acquired mutations. AML evolution thus mainly involved modification of subclones while the clonal background remained unchanged. NPM1 mutations were identified as the most probable leukaemia-transformation lesion, remaining conserved in contrast to high variation of accompanying subclonal FLT3 and NRAS mutations. DNMT3A mutations represented the most stable mutations forming a preleukaemic background in most samples. Mutations in genes IDH1/2, TET2, RUNX1, ASXL1 and U2AF1 were detected both as preleukaemic and as subclonal lesions, suggesting a non-specific order of acquisition.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a klonální evoluce $7 D060965
- 650 _2
- $a buněčné klony $7 D002999
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a geny nádorové $7 D052138
- 650 _2
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a heterografty $7 D064593
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a akutní myeloidní leukemie $x farmakoterapie $x genetika $x terapie $7 D015470
- 650 _2
- $a leukocyty $7 D007962
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední NOD $7 D016688
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a nádorové proteiny $x genetika $7 D009363
- 650 _2
- $a transplantace nádorů $7 D009368
- 650 _2
- $a nádorové kmenové buňky $7 D014411
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Culen, Martin $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Folta, Adam $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Jeziskova, Ivana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Cerna, Jana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Loja, Tomas $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Tom, Nikola $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Smejkal, Jiri $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Semerad, Lukas $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Dvorakova, Dana $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Mayer, Jiri $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Racil, Zdenek $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic ; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 190, č. 4 (2020), s. 562-572
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31822038 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210714132202 $b ABA008
- 999 __
- $a ok $b bmc $g 1650632 $s 1132681
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 190 $c 4 $d 562-572 $e 20191210 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- GRA __
- $a MUNI/A/1105/2018 $p Masarykova Univerzita
- GRA __
- $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20210420